Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Pancreatic Neoplasms 70Neoplasms 56Neoplasm Metastasis 32Brain Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Glioblastoma 24Adenocarcinoma of Lung 23Gliosarcoma 22Non-Squamous Non-Small Cell Lung Cancer 21Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma, Bronchiolo-Alveolar 16Rectal Neoplasms 13Colonic Neoplasms 13Carcinoma, Renal Cell 13Glioma 12Esophageal Neoplasms 11Astrocytoma 11Central Nervous System Neoplasms 9Carcinoma, Squamous Cell 9Salivary Gland Neoplasms 8Prostatic Neoplasms 8Oligodendroglioma 8Gallbladder Neoplasms 8Adenocarcinoma 8Ovarian Neoplasms 7

Interventions

Cisplatin 29Magnetic Resonance Spectroscopy 16Specimen Handling 13Radiotherapy 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Surgical Procedures, Operative 9Paclitaxel 9Fluorouracil 9Docetaxel 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Radiation 6Carboplatin 6Taxes 5Biopsy 5toripalimab 4X-Rays 4Surveys and Questionnaires 4Fluorodeoxyglucose F18 4Chemoradiotherapy 4Celecoxib 4(225)Ac-DOTA-c(RGDyK) 4Immunohistochemistry 3Counseling 3130-nm albumin-bound paclitaxel 3motexafin gadolinium 2ipatasertib 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypopharyngeal Neoplasms × Erlotinib Hydrochloride × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡